Basic Provera Information

• INN (International Nonproprietary Name): Medroxyprogesterone Acetate.
• Brand Names Available In United Kingdom: Provera (various generics).
• ATC Code: G03DA02.
• Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 10 mg in bottles of 30–500; injectable Depo‑Provera 150 mg/mL (IM) and Depo‑SubQ Provera 104 mg/0.65 mL (SQ).
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Not specified.
• OTC / Rx Classification: Prescription only (Rx).

Key Findings From Recent Trials

What do recent trials tell us about depot and oral medroxyprogesterone acetate?

Large randomised trials from 2022–2025 focused on contraceptive efficacy and comparative oral regimens for endometrial protection.

Depo‑SubQ 104 mg has demonstrated non‑inferiority to Depo‑Provera 150 mg IM for pregnancy prevention when injections are given on schedule.

Cohort registries reinforced contraceptive reliability for both depot formulations provided dose intervals are maintained.

Oral medroxyprogesterone acetate regimens of 5–10 mg daily achieved good cycle control in trials for abnormal uterine bleeding and endometrial hyperplasia management.

Safety analyses consistently flagged two clinically important signals to discuss with patients: bone mineral density changes and mood or menstrual pattern shifts.

BMD reductions seen with prolonged injectable use were generally reversible and prompt recommendations to reassess continuous use beyond around two years.

Mood changes and menstrual irregularities were commonly reported but were usually non‑serious in trial safety datasets.

Contraindications such as thromboembolic disease, liver dysfunction and breast cancer remained consistent across subanalyses and labelling.

These findings inform UK prescribers on counselling, choosing between oral Provera tablets and depot injections, and timing follow‑up checks.

Clinical Mechanism Of Action

How does Provera actually work in plain terms?

Medroxyprogesterone acetate mimics natural progesterone to stabilise the womb lining, help control bleeding and, with depot injections, suppress ovulation.

At a scientific level MPA binds progesterone receptors in the hypothalamic–pituitary–ovarian axis to reduce gonadotrophin release and ovulatory signalling.

Endometrial binding induces secretory transformation and reduced proliferation, which is why Provera is used for abnormal uterine bleeding and to protect the endometrium during oestrogen therapy.

Receptor pharmacology shows high affinity for PR‑A and PR‑B, and some glucocorticoid receptor activity at higher doses which explains metabolic and mood effects.

Formulation determines clinical effect: oral tablets (2.5–10 mg) provide systemic progestogenic exposure for cycle control.

Depot injections (104 mg SQ or 150 mg IM) create sustained plasma levels that suppress ovulation and provide long‑acting contraception.

Understanding these differences helps patients choose between short‑course progestogen tablets and low‑maintenance injectable contraception like Depo‑Provera and Depo‑SubQ.

Scope Of Approved & Off‑Label Use

Which uses are licensed in the UK and what do clinicians do off‑label?

Licensed indications for Provera tablets include secondary amenorrhoea, abnormal uterine bleeding and endometrial protection during oestrogen therapy.

Standard oral regimens are 5 or 10 mg daily for 5–10 days for bleeding control, and 5 or 10 mg daily for 12–14 days per month for HRT endometrial protection.

Depot preparations such as Depo‑Provera and Depo‑SubQ are licensed contraceptives administered every 12–13 weeks.

Off‑label trends in practice include short‑term use for heavy menstrual bleeding when intrauterine options are unsuitable and compassionate use in selected hormone‑sensitive situations.

UK guidance advises that providers weigh BMD and thromboembolic risks when discussing long‑term injectable contraception with patients.

Prescribers should consult the relevant SmPC and local formularies when choosing Provera tablets, Depo‑Provera or Depo‑SubQ for an individual patient.

Dosage Strategy

What dosing approaches are used for different conditions?

General oral dosing follows SmPC guidance with tablets available as 2.5 mg, 5 mg and 10 mg strengths for pulse or cyclical courses.

For abnormal uterine bleeding or secondary amenorrhoea the common schedule is 5 or 10 mg daily for 5–10 days, often started on cycle day 16–21.

For endometrial hyperplasia or combined HRT protection dosing is usually 5 or 10 mg daily for 12–14 consecutive days each month while oestrogen continues.

Injectable contraception uses Depo‑Provera 150 mg IM every three months, or Depo‑SubQ Provera 104 mg SQ every three months.

Missed oral doses should be taken the same day if remembered; if close to the next dose, skip and continue—do not double up.

For a missed injection administer as soon as possible and advise backup contraception according to timing and sexual activity.

Use caution and individualise dosing in hepatic impairment because MPA is hepatically metabolised, and reassess prolonged injectable use due to BMD concerns beyond approximately two years.

Safety Protocols

What are the main safety checks before prescribing Provera?

Absolute contraindications include hypersensitivity to medroxyprogesterone acetate, active or prior thromboembolic disease, diagnosed or suspected breast or genital malignancy, undiagnosed vaginal bleeding, significant liver disease and pregnancy.

Common adverse effects are menstrual irregularities such as spotting or amenorrhoea, weight gain, headache, breast tenderness, bloating, nausea and mood changes.

Injectables may also cause injection‑site reactions and the long‑term safety signal of reversible bone mineral density reduction requires clinician discussion.

Relative contraindications needing caution include a history of depression, migraine, epilepsy, cardiovascular risk factors, diabetes with vascular complications, asthma and hypertension.

Counsel patients on signs of thromboembolism, severe abdominal pain suggestive of liver problems, and breast changes that require assessment.

Document baseline bone risk if starting long‑term depot contraception and monitor mental health in those with pre‑existing mood disorders.

Interaction Mapping

Are there important drug or food interactions to worry about?

There are no major food restrictions for medroxyprogesterone acetate; tablets may be taken with or without food for convenience.

Drug interactions centre on hepatic enzyme induction and inhibition that change systemic progestogen exposure.

Strong hepatic enzyme inducers such as rifampicin and certain anticonvulsants (carbamazepine, phenytoin, phenobarbital) can reduce effectiveness of progestogen tablets and potentially reduce injectable duration of reliable contraception.

When a patient is on enzyme inducers consider alternative contraception or counselling about reduced effectiveness and need for backup methods.

Strong inhibitors may raise exposure to MPA so monitor for increased adverse effects when co‑prescribing potent azoles or other inhibitors.

Anticoagulant doses do not usually require routine change when starting progestogen therapy, but active or recent thromboembolic disease is a contraindication.

Always check the SmPC and local resources such as the BNF when managing complex combinations.

Patient Experience Analysis

What do patients report about tablets versus injections in real life?

Survey data show many patients welcome the convenience of three‑monthly injections like Depo‑Provera or Depo‑SubQ and appreciate reliable contraception without daily pills.

Common concerns reported in cohorts and forums include delayed return to fertility after injectables and perceived weight gain with both oral and depot formulations.

Tablet users often value rapid return of fertility after stopping and report more frequent short‑term menstrual irregularities during initiation.

Online discussions regularly highlight mood changes and menstrual unpredictability as reasons for discontinuation of progestogen tablets.

Injection‑site soreness and weight change are frequent complaints for depot users, and patients often want explicit discussion about bone density effects with prolonged injectable use.

Shared decision‑making and clear documentation of informed consent, including discussion of alternatives like levonorgestrel IUS, help align treatment with patient priorities.

Distribution & Pricing Landscape

Who supplies Provera and what are typical UK pricing considerations?

Pfizer is the primary global owner and supplier of Provera, and multiple generics supply European and UK markets.

Products on the market include oral Provera tablets in 2.5, 5 and 10 mg strengths and injectable Depo‑Provera 150 mg/mL or Depo‑SubQ 104 mg preparations.

On the NHS formulary Provera tablets are typically inexpensive generics, while depot injections are costed higher because of device and administration expenses.

Private clinic fees for administration are a major part of the price for injectable contraception in a non‑NHS setting.

Storage and logistics influence procurement: tablets are stored at or below 25–30°C, while injectables are stored at 15–30°C and protected from light.

In our online pharmacy, provera is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

When might a prescriber choose something other than Provera?

Levonorgestrel intrauterine systems are often preferred for heavy menstrual bleeding due to high efficacy and low systemic exposure.

Micronised progesterone may be better tolerated by some patients with mood sensitivity, though it is less reliable for contraception.

Norethindrone acetate is a close oral alternative for abnormal uterine bleeding with a different side‑effect profile.

Dydrogesterone and other progestins are used in Europe depending on availability and individual patient factors.

Combined hormonal options are effective for cycle control but are unsuitable if a patient has significant thrombotic risk.

Choosing between Provera tablets, depot injections or an LNG‑IUS should take account of fertility plans, bone health, mood history and procedural preferences.

Regulatory Status

Which agencies regulate medroxyprogesterone acetate and what do labels emphasise?

Medroxyprogesterone acetate products carry the ATC code G03DA02 and are regulated by national agencies across jurisdictions.

In Europe the product is prescription‑only and national SmPCs align on absolute contraindications and standard dosing regimens for oral and injectable forms.

Key SmPC highlights include contraindications for thromboembolic disease, breast or genital malignancy, undiagnosed vaginal bleeding, significant liver disease and pregnancy.

SmPCs specify oral dosing of 5–10 mg in pulse or cyclical regimens and injectable schedules of 150 mg IM or 104 mg SQ every three months.

Storage guidance in labels states tablets at ≤25–30°C and injectables at 15–30°C, protected from light and not frozen.

Regulatory safety communications commonly reiterate the reversible BMD signal with prolonged depot use and advise reassessment if use exceeds approximately two years.

Consolidated FAQ

What are the top patient questions and quick clinician tips?

Top Patient Questions:

1) Will Provera stop my period? Short oral courses usually control bleeding and injectables commonly cause amenorrhoea over time.

2) Is fertility affected? Oral effects reverse quickly; injectables may delay return to fertility for several months.

3) Can I use while breastfeeding? Discuss with a clinician; intrauterine methods are often preferred when breastfeeding is a priority.

4) Is it safe with liver disease? Significant liver dysfunction is a contraindication.

5) What about weight gain? Weight change is commonly reported and should be discussed up front.

Clinician Pointers:

Screen for thromboembolic history, assess baseline bone risk for planned long‑term depot use, review mood history and check for interacting medicines such as enzyme inducers.

Document informed consent, give missed‑dose instructions and schedule follow‑up reviews in line with the SmPC.

Visual Guide

Which images and infographics help patients and clinic teams?

Useful images include labelled tablet packs for 2.5, 5 and 10 mg Provera tablets and photos of prefilled syringes or vials for Depo‑Provera 150 mg/mL and Depo‑SubQ 104 mg/0.65 mL.

A clear visual comparing tablets versus injectables should show dosing frequency, onset and offset of fertility, and common side‑effect icons for mood, weight and bone density.

Infographic elements for clinics ought to include a selection flowchart from contraindications to formulation choice, a missed‑dose decision tree and storage temperature bands.

A clinic poster summarising follow‑up timing and when to seek urgent care (leg pain, chest pain, jaundice) supports safer prescribing and informed consent.

Storage & Transport

What are practical storage rules for pharmacy and clinic stock?

Provera tablets should be stored at or below 25–30°C, kept in original packaging and out of reach of children.

Avoid exposing tablets to excessive humidity and do not dispense tablets that show physical degradation.

Depo‑Provera and Depo‑SubQ should be stored between 15–30°C, protected from light and never frozen.

Transport should keep products within recommended ambient ranges and include temperature logs when extremes are possible.

Expired medications must be handled via pharmacy returns, and clinical sharps waste from injections should follow UK clinical waste regulations.

Guidelines For Proper Use

What should prescribers checklist and counselling cover before starting Provera?

Prescriber Checklist:

Confirm indication and formulation choice, review SmPC absolute contraindications and document any relative risks such as prior depression or osteoporosis.

Assess baseline bone health if planning injectable contraception beyond two years and check for interacting medicines like enzyme inducers.

Explain the potential for delayed return of fertility after injections and ensure informed consent is recorded.

Patient Counselling Script:

Explain purpose (cycle control or contraception), dosing schedule (oral 5–10 mg short courses; injection every 12–13 weeks), and common side effects including menstrual changes, weight and mood.

Review missed‑dose procedures, storage requirements for tablets and when to seek urgent care for signs of thromboembolism, severe abdominal pain or jaundice.

Delivery Across United Kingdom